Related Experiment Videos
Technology evaluation: ISIS-2503, Isis Pharmaceuticals
1Duke University Medical Center, Department of Medicine, Durham, NC 27710, USA. m.morse@cgct.duke.edu
Abstract:
ISIS-2503, a 20-mer antisense oligonucleotide that inhibits Ha-Ras expression, is being developed by Isis Pharmaceuticals Inc as a potential treatmentfor cancer, particularly tumors that commonly have abnormalities of Ras function. It is in phase II trials. According to an April 2001 report by Bear Stearns & Co, Elan Corp plc had an unspecified collaboration with Isis for the development of ISIS-2503 [419357], but Isis later clarified that there was no agreement between the two companies and that ISIS-2503 had merely been used for the 'OraSense' joint venture that explores the use of antisense oligonucleotidesfor oral administration [419673].
Insights
ISIS-2503, an antisense oligonucleotide targeting Ha-Ras, is under development for cancer treatment. This therapy is currently in Phase II clinical trials, showing promise for tumors with Ras pathway abnormalities.
Area of Science:
- Oncology
- Molecular Biology
- Drug Development
Background:
- Ras proteins are key regulators of cell signaling pathways.
- Abnormalities in Ras function are implicated in the development and progression of many cancers.
- Antisense oligonucleotide technology offers a targeted approach to modulate gene expression.
Purpose of the Study:
- To evaluate ISIS-2503, an antisense oligonucleotide, as a potential cancer therapeutic.
- To investigate the efficacy of inhibiting Ha-Ras expression in tumors with Ras pathway abnormalities.
Main Methods:
- ISIS-2503 is a 20-mer antisense oligonucleotide designed to inhibit Ha-Ras expression.
- The drug is currently undergoing Phase II clinical trials.
- Investigational studies explore its application in various cancer types.
Main Results:
- ISIS-2503 targets the Ha-Ras gene, a critical component in cancer cell signaling.
- The drug is being assessed for its therapeutic potential in cancers characterized by Ras pathway dysfunction.
- Clinical development is ongoing, with the compound in Phase II trials.
Conclusions:
- ISIS-2503 represents a targeted therapeutic strategy for cancers associated with Ras abnormalities.
- Further clinical evaluation is necessary to establish its safety and efficacy profile.
- The development of ISIS-2503 highlights the potential of antisense oligonucleotides in oncology.